KR101614723B1 - Mch 길항물질로서 (1-아지논)-치환된 피리도인돌 - Google Patents
Mch 길항물질로서 (1-아지논)-치환된 피리도인돌 Download PDFInfo
- Publication number
- KR101614723B1 KR101614723B1 KR1020107017685A KR20107017685A KR101614723B1 KR 101614723 B1 KR101614723 B1 KR 101614723B1 KR 1020107017685 A KR1020107017685 A KR 1020107017685A KR 20107017685 A KR20107017685 A KR 20107017685A KR 101614723 B1 KR101614723 B1 KR 101614723B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyridin
- mmol
- pyrido
- methyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IVCGJOSPVGENCT-UHFFFAOYSA-N 1h-pyrrolo[2,3-f]quinoline Chemical class N1=CC=CC2=C(NC=C3)C3=CC=C21 IVCGJOSPVGENCT-UHFFFAOYSA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title description 2
- -1 substituted Chemical class 0.000 claims abstract description 391
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 66
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 38
- 125000003118 aryl group Chemical group 0.000 claims abstract description 34
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 18
- 125000005843 halogen group Chemical group 0.000 claims abstract description 17
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 14
- 150000002367 halogens Chemical class 0.000 claims abstract description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 6
- 239000011737 fluorine Substances 0.000 claims abstract description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 473
- 238000000034 method Methods 0.000 claims description 311
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 82
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 150000003840 hydrochlorides Chemical group 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 12
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 11
- 208000008589 Obesity Diseases 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 480
- 239000007787 solid Substances 0.000 description 351
- 239000000243 solution Substances 0.000 description 343
- 239000000460 chlorine Substances 0.000 description 272
- 238000005481 NMR spectroscopy Methods 0.000 description 249
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 231
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 231
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 200
- 239000000203 mixture Substances 0.000 description 185
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 184
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 174
- 239000000725 suspension Substances 0.000 description 139
- 230000002829 reductive effect Effects 0.000 description 135
- 238000006243 chemical reaction Methods 0.000 description 129
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 126
- 238000003818 flash chromatography Methods 0.000 description 124
- 238000004128 high performance liquid chromatography Methods 0.000 description 124
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 121
- 239000000741 silica gel Substances 0.000 description 118
- 229910002027 silica gel Inorganic materials 0.000 description 118
- 239000011734 sodium Substances 0.000 description 111
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 94
- 235000019439 ethyl acetate Nutrition 0.000 description 94
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 74
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 72
- 239000011541 reaction mixture Substances 0.000 description 72
- 239000000843 powder Substances 0.000 description 67
- NRGKFNDKBDBBGY-UHFFFAOYSA-N 1h-pyridin-2-one;hydrochloride Chemical compound Cl.O=C1C=CC=CN1 NRGKFNDKBDBBGY-UHFFFAOYSA-N 0.000 description 61
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 61
- 229920006395 saturated elastomer Polymers 0.000 description 53
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 52
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 50
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- 239000012074 organic phase Substances 0.000 description 45
- 238000000746 purification Methods 0.000 description 44
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 43
- 239000012267 brine Substances 0.000 description 38
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 38
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 36
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 34
- 239000012071 phase Substances 0.000 description 34
- 239000012458 free base Substances 0.000 description 32
- 125000006239 protecting group Chemical group 0.000 description 32
- 238000009472 formulation Methods 0.000 description 31
- 239000002904 solvent Substances 0.000 description 31
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000001914 filtration Methods 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 239000003921 oil Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 238000003756 stirring Methods 0.000 description 26
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 25
- 235000019198 oils Nutrition 0.000 description 25
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 24
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 24
- 229960003540 oxyquinoline Drugs 0.000 description 24
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 22
- 239000006260 foam Substances 0.000 description 22
- 238000010511 deprotection reaction Methods 0.000 description 21
- IDCBQVLMQMNDSJ-UHFFFAOYSA-N tert-butyl 7-bromo-5-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C12=CC=C(Br)C=C2N(C)C2=C1CN(C(=O)OC(C)(C)C)CC2 IDCBQVLMQMNDSJ-UHFFFAOYSA-N 0.000 description 21
- 238000010992 reflux Methods 0.000 description 20
- 229910000104 sodium hydride Inorganic materials 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 229910052786 argon Inorganic materials 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 229910021529 ammonia Inorganic materials 0.000 description 17
- 239000008346 aqueous phase Substances 0.000 description 17
- 239000006185 dispersion Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000000284 extract Substances 0.000 description 16
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
- DOVNUEPFPBWTSV-UHFFFAOYSA-N 4-phenylmethoxy-1h-pyridin-2-one Chemical compound C1=CNC(=O)C=C1OCC1=CC=CC=C1 DOVNUEPFPBWTSV-UHFFFAOYSA-N 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 15
- 238000001816 cooling Methods 0.000 description 15
- 239000002480 mineral oil Substances 0.000 description 15
- 235000010446 mineral oil Nutrition 0.000 description 15
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 15
- JRSSLWBCCBXOCK-UHFFFAOYSA-N tert-butyl 7-bromo-9-methyl-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C12=CC=C(Br)C=C2N(C)C2=C1CCN(C(=O)OC(C)(C)C)C2 JRSSLWBCCBXOCK-UHFFFAOYSA-N 0.000 description 15
- NRESDXFFSNBDGP-UHFFFAOYSA-N (4-bromophenyl)hydrazine Chemical compound NNC1=CC=C(Br)C=C1 NRESDXFFSNBDGP-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 13
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 13
- XIUFMOWIWSJHNC-UHFFFAOYSA-N 5h-indole-2-carboxylic acid Chemical compound C1C=CC2=NC(C(=O)O)=CC2=C1 XIUFMOWIWSJHNC-UHFFFAOYSA-N 0.000 description 13
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 11
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- DPJVRASYWYOFSJ-UHFFFAOYSA-N 4-chloro-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC=C(Cl)C=C1 DPJVRASYWYOFSJ-UHFFFAOYSA-N 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 239000000443 aerosol Substances 0.000 description 9
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 150000007942 carboxylates Chemical class 0.000 description 8
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical group OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 7
- WJRKNLONLOMALV-UHFFFAOYSA-N 5-chloropyridine Chemical compound ClC1=C=NC=C[CH]1 WJRKNLONLOMALV-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 101150003085 Pdcl gene Proteins 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000007872 degassing Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- MFCWFKQMLTWWCD-UHFFFAOYSA-N 1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)-4-phenylmethoxypyridin-2-one Chemical compound C1=C2N(C)C=3CCNCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=CC=C1 MFCWFKQMLTWWCD-UHFFFAOYSA-N 0.000 description 4
- MXDRPNGTQDRKQM-UHFFFAOYSA-N 3-methylpyridazine Chemical compound CC1=CC=CN=N1 MXDRPNGTQDRKQM-UHFFFAOYSA-N 0.000 description 4
- KVEPRQPWUFQAMC-UHFFFAOYSA-N 4-(2-phenylethyl)-1h-pyridin-2-one Chemical compound C1=CNC(=O)C=C1CCC1=CC=CC=C1 KVEPRQPWUFQAMC-UHFFFAOYSA-N 0.000 description 4
- MUYUUYSIMYNEMX-UHFFFAOYSA-N 4-(pyridin-2-ylmethoxy)-1h-pyridin-2-one Chemical compound C1=CNC(=O)C=C1OCC1=CC=CC=N1 MUYUUYSIMYNEMX-UHFFFAOYSA-N 0.000 description 4
- YFTGMMXMLPTTAY-UHFFFAOYSA-N 4-bromo-2-methoxypyridine Chemical compound COC1=CC(Br)=CC=N1 YFTGMMXMLPTTAY-UHFFFAOYSA-N 0.000 description 4
- QVVRJHLMFGOKRK-UHFFFAOYSA-N 4-phenylmethoxy-1h-pyridazin-6-one Chemical compound C1=NNC(=O)C=C1OCC1=CC=CC=C1 QVVRJHLMFGOKRK-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 4
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000005932 reductive alkylation reaction Methods 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- KHGVHXBAVPSADH-UHFFFAOYSA-N tert-butyl 7-bromo-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound N1C2=CC(Br)=CC=C2C2=C1CN(C(=O)OC(C)(C)C)CC2 KHGVHXBAVPSADH-UHFFFAOYSA-N 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- ULUIXJDBPYBAHS-UHFFFAOYSA-N (2-fluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(F)=C1 ULUIXJDBPYBAHS-UHFFFAOYSA-N 0.000 description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- JMJWBINWUCHDRO-UHFFFAOYSA-N 2-(6-bromo-1h-indol-3-yl)ethanamine Chemical compound BrC1=CC=C2C(CCN)=CNC2=C1 JMJWBINWUCHDRO-UHFFFAOYSA-N 0.000 description 3
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 3
- IVEDERMVYXTQFO-UHFFFAOYSA-N 4-(4-chlorophenyl)-1h-pyridin-2-one Chemical compound C1=CC(Cl)=CC=C1C1=CC(=O)NC=C1 IVEDERMVYXTQFO-UHFFFAOYSA-N 0.000 description 3
- NTINJIKAEBJEDN-UHFFFAOYSA-N 4-(4-methoxy-2-methylphenyl)-1h-pyridin-2-one Chemical compound CC1=CC(OC)=CC=C1C1=CC(=O)NC=C1 NTINJIKAEBJEDN-UHFFFAOYSA-N 0.000 description 3
- GFHWWGJIYFJMQC-UHFFFAOYSA-N 4-(4-methoxyphenyl)-1h-pyridin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)NC=C1 GFHWWGJIYFJMQC-UHFFFAOYSA-N 0.000 description 3
- WWMWMCGANYYINN-UHFFFAOYSA-N 4-(4-methylsulfanylphenyl)-1h-pyridin-2-one Chemical compound C1=CC(SC)=CC=C1C1=CC(=O)NC=C1 WWMWMCGANYYINN-UHFFFAOYSA-N 0.000 description 3
- UIEYSIUCGSJEDB-UHFFFAOYSA-N 4-(5-methylpyridin-2-yl)-1h-pyridin-2-one Chemical compound N1=CC(C)=CC=C1C1=CC(=O)NC=C1 UIEYSIUCGSJEDB-UHFFFAOYSA-N 0.000 description 3
- XBIVQGNTQSQNKK-UHFFFAOYSA-N 4-(imidazo[1,2-a]pyridin-6-ylmethoxy)-1h-pyridin-2-one Chemical compound C1=CNC(=O)C=C1OCC1=CN2C=CN=C2C=C1 XBIVQGNTQSQNKK-UHFFFAOYSA-N 0.000 description 3
- BLVILFPFHSLKGA-UHFFFAOYSA-N 4-[(5-chloropyridin-2-yl)methoxy]-1h-pyridin-2-one Chemical compound N1=CC(Cl)=CC=C1COC1=CC(=O)NC=C1 BLVILFPFHSLKGA-UHFFFAOYSA-N 0.000 description 3
- DCOVCKYPSZJOCD-UHFFFAOYSA-N 4-[5-(trifluoromethyl)pyridin-2-yl]-1h-pyridin-2-one Chemical compound N1=CC(C(F)(F)F)=CC=C1C1=CC(=O)NC=C1 DCOVCKYPSZJOCD-UHFFFAOYSA-N 0.000 description 3
- XCPLJSUPZPYXCF-UHFFFAOYSA-N 4-[6-(trifluoromethyl)pyridazin-3-yl]-1h-pyridin-2-one Chemical compound N1=NC(C(F)(F)F)=CC=C1C1=CC(=O)NC=C1 XCPLJSUPZPYXCF-UHFFFAOYSA-N 0.000 description 3
- ZTSRJFAJTKAFEH-UHFFFAOYSA-N 4-[6-(trifluoromethyl)pyridin-3-yl]-1h-pyridin-2-one Chemical compound C1=NC(C(F)(F)F)=CC=C1C1=CC(=O)NC=C1 ZTSRJFAJTKAFEH-UHFFFAOYSA-N 0.000 description 3
- LSHHYKYAEHDOGB-UHFFFAOYSA-N 5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indole Chemical compound C12=CC=CC=C2N(C)C2=C1CNCC2 LSHHYKYAEHDOGB-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- FJNCXZZQNBKEJT-UHFFFAOYSA-N 8beta-hydroxymarrubiin Natural products O1C(=O)C2(C)CCCC3(C)C2C1CC(C)(O)C3(O)CCC=1C=COC=1 FJNCXZZQNBKEJT-UHFFFAOYSA-N 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- QHXLIQMGIGEHJP-UHFFFAOYSA-N boron;2-methylpyridine Chemical compound [B].CC1=CC=CC=N1 QHXLIQMGIGEHJP-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- ROPHYEIJSUUKEO-UHFFFAOYSA-N imidazo[1,2-a]pyridin-2-ylmethanol Chemical group C1=CC=CC2=NC(CO)=CN21 ROPHYEIJSUUKEO-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 3
- 238000011894 semi-preparative HPLC Methods 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- OSMADJAEHVCZKN-QMMMGPOBSA-N tert-butyl (2s)-2-(bromomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CBr OSMADJAEHVCZKN-QMMMGPOBSA-N 0.000 description 3
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 3
- WEUIAQBCUNERJI-UHFFFAOYSA-N tert-butyl 7-(4-hydroxy-2-oxopyridin-1-yl)-5-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N1C=CC(O)=CC1=O WEUIAQBCUNERJI-UHFFFAOYSA-N 0.000 description 3
- WJPASNZIMQXVHJ-UHFFFAOYSA-N tert-butyl 7-bromo-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carboxylate Chemical compound N1C2=CC(Br)=CC=C2C2=C1CCN(C(=O)OC(C)(C)C)C2 WJPASNZIMQXVHJ-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 2
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical group CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 2
- ATQSEAQCJZLILV-UHFFFAOYSA-N (3-bromo-4-fluoroanilino)azanium;chloride Chemical compound Cl.NNC1=CC=C(F)C(Br)=C1 ATQSEAQCJZLILV-UHFFFAOYSA-N 0.000 description 2
- PESJTQQZJJTNOC-UHFFFAOYSA-N (3-bromophenyl)hydrazine Chemical compound NNC1=CC=CC(Br)=C1 PESJTQQZJJTNOC-UHFFFAOYSA-N 0.000 description 2
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 2
- HRMRQBJUFWFQLX-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-3-carboxylic acid Chemical group CC(C)(C)OC(=O)N1CCC(C(O)=O)C1 HRMRQBJUFWFQLX-UHFFFAOYSA-N 0.000 description 2
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 2
- WUKUBLHPDQQFDB-UHFFFAOYSA-N 1-oxido-4-(pyridin-2-ylmethoxy)pyridin-1-ium Chemical compound C1=C[N+]([O-])=CC=C1OCC1=CC=CC=N1 WUKUBLHPDQQFDB-UHFFFAOYSA-N 0.000 description 2
- JNLBRMDGJDSLLQ-UHFFFAOYSA-N 1h-pyridazin-6-one;hydrochloride Chemical compound Cl.O=C1C=CC=NN1 JNLBRMDGJDSLLQ-UHFFFAOYSA-N 0.000 description 2
- AYYNMQGCYHDBQV-UHFFFAOYSA-N 1h-pyridin-2-one;dihydrochloride Chemical compound Cl.Cl.O=C1C=CC=CN1 AYYNMQGCYHDBQV-UHFFFAOYSA-N 0.000 description 2
- JSHFGBBOWCTTMU-UHFFFAOYSA-N 2-(2-methoxypyridin-4-yl)-5-(trifluoromethyl)pyrimidine Chemical compound C1=NC(OC)=CC(C=2N=CC(=CN=2)C(F)(F)F)=C1 JSHFGBBOWCTTMU-UHFFFAOYSA-N 0.000 description 2
- GUAGFYUVBQEZFB-UHFFFAOYSA-N 2-(4-bromo-1h-indol-3-yl)ethanamine Chemical compound C1=CC(Br)=C2C(CCN)=CNC2=C1 GUAGFYUVBQEZFB-UHFFFAOYSA-N 0.000 description 2
- SKORRMUMYJWDKL-UHFFFAOYSA-N 2-[(1-oxidopyridin-1-ium-4-yl)oxymethyl]imidazo[1,2-a]pyridine Chemical compound C1=C[N+]([O-])=CC=C1OCC1=CN(C=CC=C2)C2=N1 SKORRMUMYJWDKL-UHFFFAOYSA-N 0.000 description 2
- FLPNHEIQWWMKAP-UHFFFAOYSA-N 2-[(1-oxidopyridin-1-ium-4-yl)oxymethyl]pyrimidine Chemical compound C1=C[N+]([O-])=CC=C1OCC1=NC=CC=N1 FLPNHEIQWWMKAP-UHFFFAOYSA-N 0.000 description 2
- HTFXWAOSQODIBI-UHFFFAOYSA-N 2-benzyl-1,3-dihydropyrrolo[3,4-c]pyridine Chemical compound C1C2=CC=NC=C2CN1CC1=CC=CC=C1 HTFXWAOSQODIBI-UHFFFAOYSA-N 0.000 description 2
- QSECPQCFCWVBKM-UHFFFAOYSA-N 2-iodoethanol Chemical compound OCCI QSECPQCFCWVBKM-UHFFFAOYSA-N 0.000 description 2
- WLRHIBFVUGEUSF-UHFFFAOYSA-N 2-methoxy-4-(2-phenylethyl)pyridine Chemical compound C1=NC(OC)=CC(CCC=2C=CC=CC=2)=C1 WLRHIBFVUGEUSF-UHFFFAOYSA-N 0.000 description 2
- SYHICCBMPAKMBD-UHFFFAOYSA-N 2-methoxy-4-(5-methylpyridin-2-yl)pyridine Chemical compound C1=NC(OC)=CC(C=2N=CC(C)=CC=2)=C1 SYHICCBMPAKMBD-UHFFFAOYSA-N 0.000 description 2
- RSATWRUWRHUHOP-BQYQJAHWSA-N 2-methoxy-4-[(e)-2-phenylethenyl]pyridine Chemical compound C1=NC(OC)=CC(\C=C\C=2C=CC=CC=2)=C1 RSATWRUWRHUHOP-BQYQJAHWSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 2
- MTHRRXAPZOEWKG-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-1-oxidopyridin-1-ium Chemical compound C1=C[N+]([O-])=CC=C1C1=CC=C(Cl)C=C1Cl MTHRRXAPZOEWKG-UHFFFAOYSA-N 0.000 description 2
- LKKACBHNEYETDU-UHFFFAOYSA-N 4-(2-fluoro-4-methoxyphenyl)-1h-pyridin-2-one Chemical compound FC1=CC(OC)=CC=C1C1=CC(=O)NC=C1 LKKACBHNEYETDU-UHFFFAOYSA-N 0.000 description 2
- VNYKFSXKOYPZFE-UHFFFAOYSA-N 4-(2-fluoro-4-methoxyphenyl)-2-methoxypyridine Chemical compound FC1=CC(OC)=CC=C1C1=CC=NC(OC)=C1 VNYKFSXKOYPZFE-UHFFFAOYSA-N 0.000 description 2
- UBOXDMMIRBHWEY-UHFFFAOYSA-N 4-(4-chloro-2-methoxyphenyl)-1-oxidopyridin-1-ium Chemical compound COC1=CC(Cl)=CC=C1C1=CC=[N+]([O-])C=C1 UBOXDMMIRBHWEY-UHFFFAOYSA-N 0.000 description 2
- BBYPNVMUUIRAMA-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-oxidopyridin-1-ium Chemical compound C1=C[N+]([O-])=CC=C1C1=CC=C(Cl)C=C1 BBYPNVMUUIRAMA-UHFFFAOYSA-N 0.000 description 2
- RSUFAQDZXHMDAX-UHFFFAOYSA-N 4-(4-fluoro-2-methoxyphenyl)-1h-pyridin-2-one Chemical compound COC1=CC(F)=CC=C1C1=CC(=O)NC=C1 RSUFAQDZXHMDAX-UHFFFAOYSA-N 0.000 description 2
- QKAWGQHGLHGERL-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1h-pyridin-2-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(=O)NC=C1 QKAWGQHGLHGERL-UHFFFAOYSA-N 0.000 description 2
- HAPLRECYLKWCBM-UHFFFAOYSA-N 4-(5-chloropyridin-2-yl)-1h-pyridin-2-one Chemical compound N1=CC(Cl)=CC=C1C1=CC(=O)NC=C1 HAPLRECYLKWCBM-UHFFFAOYSA-N 0.000 description 2
- HZJTYZAYDCHNPM-UHFFFAOYSA-N 4-(6-methylpyridin-3-yl)-1h-pyridin-2-one Chemical compound C1=NC(C)=CC=C1C1=CC(=O)NC=C1 HZJTYZAYDCHNPM-UHFFFAOYSA-N 0.000 description 2
- ZGYPSUSUROGDCR-UHFFFAOYSA-N 4-(cyclohexylmethoxy)-1h-pyridin-2-one Chemical compound C1=CNC(=O)C=C1OCC1CCCCC1 ZGYPSUSUROGDCR-UHFFFAOYSA-N 0.000 description 2
- DVLYZDLKJRLLJA-UHFFFAOYSA-N 4-(imidazo[1,2-a]pyridin-2-ylmethoxy)-1h-pyridin-2-one Chemical compound C1=CNC(=O)C=C1OCC1=CN(C=CC=C2)C2=N1 DVLYZDLKJRLLJA-UHFFFAOYSA-N 0.000 description 2
- AYZIQENJFUPTMZ-UHFFFAOYSA-N 4-[(4-chlorophenyl)methoxy]-1h-pyridin-2-one Chemical compound C1=CC(Cl)=CC=C1COC1=CC(=O)NC=C1 AYZIQENJFUPTMZ-UHFFFAOYSA-N 0.000 description 2
- XKTPUDPIKVKANM-UHFFFAOYSA-N 4-[4-(trifluoromethyl)phenyl]-1h-pyridazin-6-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(=O)NN=C1 XKTPUDPIKVKANM-UHFFFAOYSA-N 0.000 description 2
- WCUQNWUEDAJKJG-UHFFFAOYSA-N 4-[4-(trifluoromethyl)phenyl]-1h-pyridin-2-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(=O)NC=C1 WCUQNWUEDAJKJG-UHFFFAOYSA-N 0.000 description 2
- DUSGCMMHYSGPJD-UHFFFAOYSA-N 4-[5-(trifluoromethyl)pyrimidin-2-yl]-1h-pyridin-2-one Chemical compound N1=CC(C(F)(F)F)=CN=C1C1=CC(=O)NC=C1 DUSGCMMHYSGPJD-UHFFFAOYSA-N 0.000 description 2
- QDUVQUPJGGLCLY-UHFFFAOYSA-N 4-[[4-(trifluoromethyl)phenyl]methoxy]-1h-pyridin-2-one Chemical compound C1=CC(C(F)(F)F)=CC=C1COC1=CC(=O)NC=C1 QDUVQUPJGGLCLY-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- FQCNCPMIZRZAIZ-UHFFFAOYSA-N 5-fluoro-2-[(1-oxidopyridin-1-ium-4-yl)oxymethyl]pyridine Chemical compound C1=C[N+]([O-])=CC=C1OCC1=CC=C(F)C=N1 FQCNCPMIZRZAIZ-UHFFFAOYSA-N 0.000 description 2
- XEJODUJGYLVMMC-UHFFFAOYSA-N 6-[(1-oxidopyridin-1-ium-4-yl)oxymethyl]imidazo[1,2-a]pyridine Chemical compound C1=C[N+]([O-])=CC=C1OCC1=CN2C=CN=C2C=C1 XEJODUJGYLVMMC-UHFFFAOYSA-N 0.000 description 2
- MAQAGRJURDEYDQ-UHFFFAOYSA-N 6-methylpyridine Chemical compound CC1=C=CC=C[N]1 MAQAGRJURDEYDQ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OECBMRSDHCYADD-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CC2=C(N(C=3C=C(C=CC23)N2CC=C(C=C2)C=2N=NC(=CC2)C)C)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CC2=C(N(C=3C=C(C=CC23)N2CC=C(C=C2)C=2N=NC(=CC2)C)C)CC1 OECBMRSDHCYADD-UHFFFAOYSA-N 0.000 description 2
- FURFLZPWOBBTDN-UHFFFAOYSA-N CC(C)(C)C1NCCC2=C1N(C)C1=CC(Br)=CC=C21 Chemical compound CC(C)(C)C1NCCC2=C1N(C)C1=CC(Br)=CC=C21 FURFLZPWOBBTDN-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 description 2
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- JWWVWJOIKZNCSU-UHFFFAOYSA-N methanesulfonic acid;2,2,2-trifluoroacetic acid Chemical compound CS(O)(=O)=O.OC(=O)C(F)(F)F JWWVWJOIKZNCSU-UHFFFAOYSA-N 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NFCJFUKDEURMOW-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-[2-(trifluoromethyl)pyrimidin-5-yl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=CN=C(C(F)(F)F)N=C1 NFCJFUKDEURMOW-UHFFFAOYSA-N 0.000 description 2
- UXSYGXMMPRGFMN-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-[5-(trifluoromethyl)pyridin-2-yl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=CC=C(C(F)(F)F)C=N1 UXSYGXMMPRGFMN-UHFFFAOYSA-N 0.000 description 2
- MWVCFNFZXPVSSK-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-[5-(trifluoromethyl)pyrimidin-2-yl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=NC=C(C(F)(F)F)C=N1 MWVCFNFZXPVSSK-UHFFFAOYSA-N 0.000 description 2
- CWPZALYLCPVYJR-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-[6-(trifluoromethyl)pyridazin-3-yl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=CC=C(C(F)(F)F)N=N1 CWPZALYLCPVYJR-UHFFFAOYSA-N 0.000 description 2
- AMVUEMLCICCWPG-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-[6-(trifluoromethyl)pyridin-3-yl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=CC=C(C(F)(F)F)N=C1 AMVUEMLCICCWPG-UHFFFAOYSA-N 0.000 description 2
- CZLGESIIMKCBEP-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-[[6-(trifluoromethyl)pyridin-3-yl]methoxy]pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=C(C(F)(F)F)N=C1 CZLGESIIMKCBEP-UHFFFAOYSA-N 0.000 description 2
- DDUJJQUROUAQCF-UHFFFAOYSA-N tert-butyl 6-bromo-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound N1C2=CC=C(Br)C=C2C2=C1CN(C(=O)OC(C)(C)C)CC2 DDUJJQUROUAQCF-UHFFFAOYSA-N 0.000 description 2
- WORZFDBPEROPNM-UHFFFAOYSA-N tert-butyl 7-bromo-1,9-dimethyl-1,3,4,9-tetrahydropyrido[4,3-b]indole-2-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)C(C)C2=C3C(C)C=C(Br)C=C3N=C21 WORZFDBPEROPNM-UHFFFAOYSA-N 0.000 description 2
- VNMXRSUYHLGZEL-UHFFFAOYSA-N tert-butyl 7-bromo-3,3,9-trimethyl-1,4-dihydropyrido[3,4-b]indole-2-carboxylate Chemical compound C12=CC=C(Br)C=C2N(C)C2=C1CC(C)(C)N(C(=O)OC(C)(C)C)C2 VNMXRSUYHLGZEL-UHFFFAOYSA-N 0.000 description 2
- HJTTYURDNMTTSK-UHFFFAOYSA-N tert-butyl 7-bromo-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound N1C2=CC(Br)=CC=C2C2=C1CN(C(=O)OC(C)(C)C)C(C)(C)C2 HJTTYURDNMTTSK-UHFFFAOYSA-N 0.000 description 2
- DEPVQLHPDLCZGO-UHFFFAOYSA-N tert-butyl 7-bromo-5-(4-methylphenyl)sulfonyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=CC(Br)=CC=C2C2=C1CCN(C(=O)OC(C)(C)C)C2 DEPVQLHPDLCZGO-UHFFFAOYSA-N 0.000 description 2
- LQBYSHQTVWQMON-UHFFFAOYSA-N tert-butyl 7-bromo-5-tri(propan-2-yl)silyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C12=CC=C(Br)C=C2N([Si](C(C)C)(C(C)C)C(C)C)C2=C1CN(C(=O)OC(C)(C)C)CC2 LQBYSHQTVWQMON-UHFFFAOYSA-N 0.000 description 2
- ROGXQOGFVPNPOX-UHFFFAOYSA-N tert-butyl 7-bromo-6-fluoro-9-methyl-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C12=CC(F)=C(Br)C=C2N(C)C2=C1CCN(C(=O)OC(C)(C)C)C2 ROGXQOGFVPNPOX-UHFFFAOYSA-N 0.000 description 2
- ANLQTIUFOXVSAZ-UHFFFAOYSA-N tert-butyl 7-bromo-8-fluoro-5-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C12=CC(F)=C(Br)C=C2N(C)C2=C1CN(C(=O)OC(C)(C)C)CC2 ANLQTIUFOXVSAZ-UHFFFAOYSA-N 0.000 description 2
- QCTMYBBGXIVOJP-UHFFFAOYSA-N tert-butyl 7-bromo-9-(4-methylphenyl)sulfonyl-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=CC(Br)=CC=C2C2=C1CN(C(=O)OC(C)(C)C)CC2 QCTMYBBGXIVOJP-UHFFFAOYSA-N 0.000 description 2
- ZKSHZWVADFUTGD-UHFFFAOYSA-N tert-butyl 7-bromo-9-(difluoromethyl)-1,3,4,9-tetrahydropyrido[4,3-b]indole-2-carboxylate Chemical compound BrC1=CC(C(F)F)C2=C(CN(C(=O)OC(C)(C)C)CC3)C3=NC2=C1 ZKSHZWVADFUTGD-UHFFFAOYSA-N 0.000 description 2
- KYJBJCKQFOBSCM-UHFFFAOYSA-N tert-butyl 9-(4-methylphenyl)sulfonyl-7-[2-oxo-4-[4-(trifluoromethyl)phenyl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=CC(N3C(C=C(C=C3)C=3C=CC(=CC=3)C(F)(F)F)=O)=CC=C2C2=C1CN(C(=O)OC(C)(C)C)CC2 KYJBJCKQFOBSCM-UHFFFAOYSA-N 0.000 description 2
- IKDPPYIABNWVMI-UHFFFAOYSA-N tert-butyl 9-methyl-7-[2-oxo-4-[5-(trifluoromethyl)pyridin-2-yl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CN(C(=O)OC(C)(C)C)CCC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=CC=C(C(F)(F)F)C=N1 IKDPPYIABNWVMI-UHFFFAOYSA-N 0.000 description 2
- CLDNZZINGZZPER-UHFFFAOYSA-N tert-butyl 9-methyl-7-[2-oxo-4-[6-(trifluoromethyl)pyridin-3-yl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CN(C(=O)OC(C)(C)C)CCC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=CC=C(C(F)(F)F)N=C1 CLDNZZINGZZPER-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- QNEGDGPAXKYZHZ-UHFFFAOYSA-N (2,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1Cl QNEGDGPAXKYZHZ-UHFFFAOYSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-SSDOTTSWSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)=O ZQEBQGAAWMOMAI-SSDOTTSWSA-N 0.000 description 1
- RPYIPFXHIKXRKS-UHFFFAOYSA-N (3-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=CC(Br)=C1 RPYIPFXHIKXRKS-UHFFFAOYSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- RGGOWBBBHWTTRE-UHFFFAOYSA-N (4-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Br)C=C1 RGGOWBBBHWTTRE-UHFFFAOYSA-N 0.000 description 1
- YBNDRTRLXPEWKQ-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1F YBNDRTRLXPEWKQ-UHFFFAOYSA-N 0.000 description 1
- NZRRMTBNTSBIFH-UHFFFAOYSA-N (4-chloro-2-methoxyphenyl)boronic acid Chemical compound COC1=CC(Cl)=CC=C1B(O)O NZRRMTBNTSBIFH-UHFFFAOYSA-N 0.000 description 1
- PTHGDVCPCZKZKR-UHFFFAOYSA-N (4-chlorophenyl)methanol Chemical compound OCC1=CC=C(Cl)C=C1 PTHGDVCPCZKZKR-UHFFFAOYSA-N 0.000 description 1
- ADJBXDCXYMCCAD-UHFFFAOYSA-N (4-fluoro-2-methoxyphenyl)boronic acid Chemical compound COC1=CC(F)=CC=C1B(O)O ADJBXDCXYMCCAD-UHFFFAOYSA-N 0.000 description 1
- IVUHTLFKBDDICS-UHFFFAOYSA-N (4-methylsulfanylphenyl)boronic acid Chemical compound CSC1=CC=C(B(O)O)C=C1 IVUHTLFKBDDICS-UHFFFAOYSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- 150000000185 1,3-diols Chemical class 0.000 description 1
- MXFUQWVSPVTIIP-UHFFFAOYSA-N 1-(2,5-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-7-yl)-4-phenylmethoxypyridin-2-one Chemical compound C1N(C)CCC(N(C2=C3)C)=C1C2=CC=C3N(C(C=1)=O)C=CC=1OCC1=CC=CC=C1 MXFUQWVSPVTIIP-UHFFFAOYSA-N 0.000 description 1
- FSNGFFWICFYWQC-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine;hydron;chloride Chemical compound Cl.ClCCN1CCCC1 FSNGFFWICFYWQC-UHFFFAOYSA-N 0.000 description 1
- WXAPBXVONWRIMM-UHFFFAOYSA-N 1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)-4-(pyridin-2-ylmethoxy)pyridin-2-one Chemical compound C1=C2N(C)C=3CCNCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=CC=N1 WXAPBXVONWRIMM-UHFFFAOYSA-N 0.000 description 1
- FIPDNCPXUGNILC-UHFFFAOYSA-N 1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)-4-[4-(trifluoromethyl)phenyl]pyridin-2-one;dihydrochloride Chemical compound Cl.Cl.C1=C2N(C)C=3CCNCC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=CC=C(C(F)(F)F)C=C1 FIPDNCPXUGNILC-UHFFFAOYSA-N 0.000 description 1
- ICABWHAONBYHDE-UHFFFAOYSA-N 1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)-4-[[4-(trifluoromethyl)phenyl]methoxy]pyridin-2-one;dihydrochloride Chemical compound Cl.Cl.C1=C2N(C)C=3CCNCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=C(C(F)(F)F)C=C1 ICABWHAONBYHDE-UHFFFAOYSA-N 0.000 description 1
- CRWXTXGCCWDPQN-UHFFFAOYSA-N 1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)-4-phenylmethoxypyridin-2-one;hydrochloride Chemical compound Cl.C1=C2N(C)C=3CCNCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=CC=C1 CRWXTXGCCWDPQN-UHFFFAOYSA-N 0.000 description 1
- XELMCQMKCTZJSH-UHFFFAOYSA-N 1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-8-yl)-4-phenylmethoxypyridin-2-one;hydrochloride Chemical compound Cl.C=1C=C2N(C)C=3CCNCC=3C2=CC=1N(C(C=1)=O)C=CC=1OCC1=CC=CC=C1 XELMCQMKCTZJSH-UHFFFAOYSA-N 0.000 description 1
- LFPQPPIDYDOMNK-UHFFFAOYSA-N 1-(8-fluoro-2,5-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-7-yl)-4-phenylmethoxypyridin-2-one Chemical compound C1N(C)CCC(N(C2=C3)C)=C1C2=CC(F)=C3N(C(C=1)=O)C=CC=1OCC1=CC=CC=C1 LFPQPPIDYDOMNK-UHFFFAOYSA-N 0.000 description 1
- LNZGMIXOVWKNTI-UHFFFAOYSA-N 1-(8-fluoro-5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)-4-phenylmethoxypyridin-2-one Chemical compound C1=C2N(C)C=3CCNCC=3C2=CC(F)=C1N(C(C=1)=O)C=CC=1OCC1=CC=CC=C1 LNZGMIXOVWKNTI-UHFFFAOYSA-N 0.000 description 1
- ASAAKNKHYPJQGZ-UHFFFAOYSA-N 1-(9-methyl-1,2,3,4-tetrahydropyrido[3,4-b]indol-7-yl)-4-[4-(trifluoromethyl)phenyl]pyridin-2-one Chemical compound C1=C2N(C)C=3CNCCC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=CC=C(C(F)(F)F)C=C1 ASAAKNKHYPJQGZ-UHFFFAOYSA-N 0.000 description 1
- KONFCHNZHCNKIB-UHFFFAOYSA-N 1-(imidazo[1,2-a]pyridin-2-ylmethoxy)pyridin-2-one Chemical compound N=1C(=CN2C=1C=CC=C2)CON1C(C=CC=C1)=O KONFCHNZHCNKIB-UHFFFAOYSA-N 0.000 description 1
- FMXPXHJTDNIMMP-UHFFFAOYSA-N 1-[9-methyl-2-(2-pyrrolidin-1-ylacetyl)-3,4-dihydro-1h-pyrido[3,4-b]indol-7-yl]-4-phenylmethoxypyridin-2-one;hydrochloride Chemical compound Cl.C1=C2N(C)C=3CN(C(=O)CN4CCCC4)CCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=CC=C1 FMXPXHJTDNIMMP-UHFFFAOYSA-N 0.000 description 1
- AHEIBKSLGDBWLR-UQIIZPHYSA-N 1-[9-methyl-2-[(2s)-pyrrolidine-2-carbonyl]-3,4-dihydro-1h-pyrido[3,4-b]indol-7-yl]-4-phenylmethoxypyridin-2-one;hydrochloride Chemical compound Cl.C1=C2N(C)C=3CN(C(=O)[C@H]4NCCC4)CCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=CC=C1 AHEIBKSLGDBWLR-UQIIZPHYSA-N 0.000 description 1
- MPYJHMYTTXAUMC-IKXQUJFKSA-N 1-[9-methyl-2-[[(2s)-pyrrolidin-2-yl]methyl]-3,4-dihydro-1h-pyrido[3,4-b]indol-7-yl]-4-phenylmethoxypyridin-2-one;dihydrochloride Chemical compound Cl.Cl.C1CC=2C3=CC=C(N4C(C=C(OCC=5C=CC=CC=5)C=C4)=O)C=C3N(C)C=2CN1C[C@@H]1CCCN1 MPYJHMYTTXAUMC-IKXQUJFKSA-N 0.000 description 1
- YZMHTFXQZHZJSM-UHFFFAOYSA-N 1-oxido-4-[4-(trifluoromethyl)phenyl]pyridin-1-ium Chemical compound C1=C[N+]([O-])=CC=C1C1=CC=C(C(F)(F)F)C=C1 YZMHTFXQZHZJSM-UHFFFAOYSA-N 0.000 description 1
- AKWSFGDVUOJHNJ-UHFFFAOYSA-N 1-oxido-4-[[4-(trifluoromethyl)phenyl]methoxy]pyridin-1-ium Chemical compound C1=C[N+]([O-])=CC=C1OCC1=CC=C(C(F)(F)F)C=C1 AKWSFGDVUOJHNJ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- NCEUXLXYVKSJRM-UHFFFAOYSA-N 1h-pyridin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1C=CC=CN1 NCEUXLXYVKSJRM-UHFFFAOYSA-N 0.000 description 1
- RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 1
- RPROHCOBMVQVIV-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCNC2 RPROHCOBMVQVIV-UHFFFAOYSA-N 0.000 description 1
- BQHKABBJVFVZNX-UHFFFAOYSA-N 2,3,4,5-tetramethyl-1,10-phenanthroline Chemical compound N1=CC=CC2=CC(C)=C(C(C)=C(C(C)=N3)C)C3=C21 BQHKABBJVFVZNX-UHFFFAOYSA-N 0.000 description 1
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
- ZSASNSKTBRWERQ-UHFFFAOYSA-N 2,9-dimethyl-3,4-dihydro-1h-pyrido[3,4-b]indole Chemical compound CN1C2=CC=CC=C2C2=C1CN(C)CC2 ZSASNSKTBRWERQ-UHFFFAOYSA-N 0.000 description 1
- UKBKWNLKTFJOBN-UHFFFAOYSA-N 2-(2-methoxyphenyl)pyrimidine Chemical compound COC1=CC=CC=C1C1=NC=CC=N1 UKBKWNLKTFJOBN-UHFFFAOYSA-N 0.000 description 1
- RBPGKJOFYZZVEX-UHFFFAOYSA-N 2-(3-methylbutyl)-1,3-dioxolane Chemical compound CC(C)CCC1OCCO1 RBPGKJOFYZZVEX-UHFFFAOYSA-N 0.000 description 1
- CGHUQJRRADEHTQ-UHFFFAOYSA-N 2-(5-bromo-1h-indol-3-yl)ethanamine Chemical compound C1=C(Br)C=C2C(CCN)=CNC2=C1 CGHUQJRRADEHTQ-UHFFFAOYSA-N 0.000 description 1
- HSEQCUDNVLWXLJ-UHFFFAOYSA-N 2-(6-bromo-5-fluoro-1h-indol-3-yl)ethanamine Chemical compound BrC1=C(F)C=C2C(CCN)=CNC2=C1 HSEQCUDNVLWXLJ-UHFFFAOYSA-N 0.000 description 1
- UMXIAVUQROUXKO-UHFFFAOYSA-N 2-(bromomethyl)-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(CBr)N=C1 UMXIAVUQROUXKO-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- RTAGWYRXLZXYEN-UHFFFAOYSA-N 2-(oxan-2-yl)-5-[4-(trifluoromethyl)phenyl]pyridazin-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(=O)N(C2OCCCC2)N=C1 RTAGWYRXLZXYEN-UHFFFAOYSA-N 0.000 description 1
- FVLACCGUMXRPGG-UHFFFAOYSA-N 2-(pyridin-4-yloxymethyl)imidazo[1,2-a]pyridine Chemical compound C=1N2C=CC=CC2=NC=1COC1=CC=NC=C1 FVLACCGUMXRPGG-UHFFFAOYSA-N 0.000 description 1
- ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 description 1
- BQDJLAWUTBCDHK-UHFFFAOYSA-N 2-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=NC=CC=N1 BQDJLAWUTBCDHK-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- TZNJHEHAYZJBHR-UHFFFAOYSA-N 2-bromo-1,1,1-trifluoroethane Chemical compound FC(F)(F)CBr TZNJHEHAYZJBHR-UHFFFAOYSA-N 0.000 description 1
- AAOSLLBWWRKJIR-UHFFFAOYSA-N 2-chloro-1-pyrrolidin-1-ylethanone Chemical compound ClCC(=O)N1CCCC1 AAOSLLBWWRKJIR-UHFFFAOYSA-N 0.000 description 1
- RLHAGSICYJAHMN-UHFFFAOYSA-N 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound C1=NC(OC)=CC(B2OC(C)(C)C(C)(C)O2)=C1 RLHAGSICYJAHMN-UHFFFAOYSA-N 0.000 description 1
- NEDZEPOLTRMYJW-UHFFFAOYSA-N 2-methoxy-4-(6-methylpyridin-3-yl)pyridine Chemical compound C1=NC(OC)=CC(C=2C=NC(C)=CC=2)=C1 NEDZEPOLTRMYJW-UHFFFAOYSA-N 0.000 description 1
- MUZASNXPUQUZFE-UHFFFAOYSA-N 2-methoxy-4-[5-(trifluoromethyl)pyridin-2-yl]pyridine Chemical compound C1=NC(OC)=CC(C=2N=CC(=CC=2)C(F)(F)F)=C1 MUZASNXPUQUZFE-UHFFFAOYSA-N 0.000 description 1
- ISVJJGDBJVDFOY-UHFFFAOYSA-N 2-methoxy-4-[6-(trifluoromethyl)pyridin-3-yl]pyridine Chemical compound C1=NC(OC)=CC(C=2C=NC(=CC=2)C(F)(F)F)=C1 ISVJJGDBJVDFOY-UHFFFAOYSA-N 0.000 description 1
- AWOVVCLZDSKFNT-UHFFFAOYSA-N 2-methoxy-4-[[6-(trifluoromethyl)pyridin-3-yl]methoxy]pyridine Chemical compound C1=NC(OC)=CC(OCC=2C=NC(=CC=2)C(F)(F)F)=C1 AWOVVCLZDSKFNT-UHFFFAOYSA-N 0.000 description 1
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 1
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 description 1
- VKIJXFIYBAYHOE-UHFFFAOYSA-N 2-phenylethenylboronic acid Chemical compound OB(O)C=CC1=CC=CC=C1 VKIJXFIYBAYHOE-UHFFFAOYSA-N 0.000 description 1
- NPAXPTHCUCUHPT-UHFFFAOYSA-N 3,4,7,8-tetramethyl-1,10-phenanthroline Chemical compound CC1=CN=C2C3=NC=C(C)C(C)=C3C=CC2=C1C NPAXPTHCUCUHPT-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- PWENPURWDBJDIM-UHFFFAOYSA-N 3-(2-methoxypyridin-4-yl)-6-(trifluoromethyl)pyridazine Chemical compound C1=NC(OC)=CC(C=2N=NC(=CC=2)C(F)(F)F)=C1 PWENPURWDBJDIM-UHFFFAOYSA-N 0.000 description 1
- VIYGGYROGHTMOI-UHFFFAOYSA-N 3-(2-methoxypyridin-4-yl)-6-methylpyridazine Chemical compound C1=NC(OC)=CC(C=2N=NC(C)=CC=2)=C1 VIYGGYROGHTMOI-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SAUGMJLWYLQPEM-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropane Chemical compound FC(F)(F)CCBr SAUGMJLWYLQPEM-UHFFFAOYSA-N 0.000 description 1
- KOWPUNQBGWIERF-UHFFFAOYSA-N 3-bromo-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Br)=C1 KOWPUNQBGWIERF-UHFFFAOYSA-N 0.000 description 1
- PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 1
- GFLPSABXBDCMCN-UHFFFAOYSA-N 4,4-diethoxybutan-1-amine Chemical compound CCOC(OCC)CCCN GFLPSABXBDCMCN-UHFFFAOYSA-N 0.000 description 1
- SARUNILMSPVWJI-UHFFFAOYSA-N 4-(1,3-dioxolan-2-yl)-2-methylbutan-2-amine Chemical compound CC(C)(N)CCC1OCCO1 SARUNILMSPVWJI-UHFFFAOYSA-N 0.000 description 1
- DZJYFDFELAEJJK-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-1h-pyridin-2-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CC(=O)NC=C1 DZJYFDFELAEJJK-UHFFFAOYSA-N 0.000 description 1
- AXRDCUPZFSYSAC-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)pyridine Chemical compound ClC1=CC(Cl)=CC=C1C1=CC=NC=C1 AXRDCUPZFSYSAC-UHFFFAOYSA-N 0.000 description 1
- ACMZBASPCQBHMQ-UHFFFAOYSA-N 4-(4-chloro-2-methoxyphenyl)-1h-pyridin-2-one Chemical compound COC1=CC(Cl)=CC=C1C1=CC(=O)NC=C1 ACMZBASPCQBHMQ-UHFFFAOYSA-N 0.000 description 1
- QSJUOJCOEZKCHR-UHFFFAOYSA-N 4-(4-chloro-2-methoxyphenyl)pyridine Chemical compound COC1=CC(Cl)=CC=C1C1=CC=NC=C1 QSJUOJCOEZKCHR-UHFFFAOYSA-N 0.000 description 1
- AVQOPXNLTUXDRU-UHFFFAOYSA-N 4-(4-chlorophenyl)pyridine Chemical compound C1=CC(Cl)=CC=C1C1=CC=NC=C1 AVQOPXNLTUXDRU-UHFFFAOYSA-N 0.000 description 1
- XVRDRZNTWHSFEN-UHFFFAOYSA-N 4-(4-fluoro-2-methoxyphenyl)-1-oxidopyridin-1-ium Chemical compound COC1=CC(F)=CC=C1C1=CC=[N+]([O-])C=C1 XVRDRZNTWHSFEN-UHFFFAOYSA-N 0.000 description 1
- RIBOMTJGOMMBPE-UHFFFAOYSA-N 4-(4-methoxy-2-methylphenyl)-1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)pyridin-2-one Chemical compound CC1=CC(OC)=CC=C1C1=CC(=O)N(C=2C=C3N(C)C=4CCNCC=4C3=CC=2)C=C1 RIBOMTJGOMMBPE-UHFFFAOYSA-N 0.000 description 1
- JJKWGJGBEJMMMY-UHFFFAOYSA-N 4-(4-methoxyphenyl)-1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)pyridin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)N(C=2C=C3N(C)C=4CCNCC=4C3=CC=2)C=C1 JJKWGJGBEJMMMY-UHFFFAOYSA-N 0.000 description 1
- CCHITUFIDZKYCS-UHFFFAOYSA-N 4-(6-methylpyridazin-3-yl)-1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)pyridin-2-one Chemical compound N1=NC(C)=CC=C1C1=CC(=O)N(C=2C=C3N(C)C=4CCNCC=4C3=CC=2)C=C1 CCHITUFIDZKYCS-UHFFFAOYSA-N 0.000 description 1
- REEIERAHLQQGAI-UHFFFAOYSA-N 4-(cyclohexylmethoxy)-1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)pyridin-2-one;hydrochloride Chemical compound Cl.C1=C2N(C)C=3CCNCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1CCCCC1 REEIERAHLQQGAI-UHFFFAOYSA-N 0.000 description 1
- AJZZSZZETAGEHR-UHFFFAOYSA-N 4-(pyrimidin-2-ylmethoxy)-1h-pyridin-2-one Chemical compound C1=CNC(=O)C=C1OCC1=NC=CC=N1 AJZZSZZETAGEHR-UHFFFAOYSA-N 0.000 description 1
- MOOUWXDQAUXZRG-UHFFFAOYSA-N 4-(trifluoromethyl)benzyl alcohol Chemical compound OCC1=CC=C(C(F)(F)F)C=C1 MOOUWXDQAUXZRG-UHFFFAOYSA-N 0.000 description 1
- FJINCRLAVMOUDZ-UHFFFAOYSA-N 4-[(4-chlorophenyl)methoxy]-1-oxidopyridin-1-ium Chemical compound C1=C[N+]([O-])=CC=C1OCC1=CC=C(Cl)C=C1 FJINCRLAVMOUDZ-UHFFFAOYSA-N 0.000 description 1
- BVZZDHFATCXUEL-UHFFFAOYSA-N 4-[(4-chlorophenyl)methoxy]pyridine Chemical compound C1=CC(Cl)=CC=C1COC1=CC=NC=C1 BVZZDHFATCXUEL-UHFFFAOYSA-N 0.000 description 1
- SYOJUQBGIVXKAD-UHFFFAOYSA-N 4-[(4-fluorophenyl)methoxy]-1h-pyridin-2-one Chemical compound C1=CC(F)=CC=C1COC1=CC(=O)NC=C1 SYOJUQBGIVXKAD-UHFFFAOYSA-N 0.000 description 1
- UWIGFKIRIDTPDF-UHFFFAOYSA-N 4-[(5-fluoropyridin-2-yl)methoxy]-1h-pyridin-2-one Chemical compound N1=CC(F)=CC=C1COC1=CC(=O)NC=C1 UWIGFKIRIDTPDF-UHFFFAOYSA-N 0.000 description 1
- CUKOVHHRGHHSJH-UHFFFAOYSA-N 4-[2-(trifluoromethyl)pyrimidin-5-yl]-1h-pyridin-2-one Chemical compound C1=NC(C(F)(F)F)=NC=C1C1=CC(=O)NC=C1 CUKOVHHRGHHSJH-UHFFFAOYSA-N 0.000 description 1
- XKLRYMRLOBCRPN-UHFFFAOYSA-N 4-[4-(trifluoromethyl)phenyl]pyridine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=NC=C1 XKLRYMRLOBCRPN-UHFFFAOYSA-N 0.000 description 1
- MVZTXJSAAHSVLK-UHFFFAOYSA-N 4-[[4-(trifluoromethyl)phenyl]methoxy]pyridine Chemical compound C1=CC(C(F)(F)F)=CC=C1COC1=CC=NC=C1 MVZTXJSAAHSVLK-UHFFFAOYSA-N 0.000 description 1
- SHTZUYDEXVQLFA-UHFFFAOYSA-N 4-[[6-(trifluoromethyl)pyridin-3-yl]methoxy]-1h-pyridin-2-one Chemical compound C1=NC(C(F)(F)F)=CC=C1COC1=CC(=O)NC=C1 SHTZUYDEXVQLFA-UHFFFAOYSA-N 0.000 description 1
- SBQVQYPJWLJRQT-UHFFFAOYSA-N 4-amino-1h-pyridin-2-one Chemical compound NC=1C=CNC(=O)C=1 SBQVQYPJWLJRQT-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- FOWOXWLATUAFNQ-UHFFFAOYSA-N 4-oxopiperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(=O)CC1 FOWOXWLATUAFNQ-UHFFFAOYSA-N 0.000 description 1
- RZGVNDQORWGSIG-UHFFFAOYSA-N 4-phenylmethoxy-1-(2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-7-yl)pyridin-2-one;hydrochloride Chemical compound Cl.C1=CN(C=2C=C3NC=4CNCCC=4C3=CC=2)C(=O)C=C1OCC1=CC=CC=C1 RZGVNDQORWGSIG-UHFFFAOYSA-N 0.000 description 1
- WBCDUONHBLSZED-UHFFFAOYSA-N 4-phenylmethoxypyridine Chemical compound C=1C=CC=CC=1COC1=CC=NC=C1 WBCDUONHBLSZED-UHFFFAOYSA-N 0.000 description 1
- ODYVZWDKDPSBKF-UHFFFAOYSA-N 4-phenylmethoxypyrimidine Chemical compound C=1C=CC=CC=1COC1=CC=NC=N1 ODYVZWDKDPSBKF-UHFFFAOYSA-N 0.000 description 1
- JZRIWCZIKIAFIJ-UHFFFAOYSA-N 5-(2-methoxypyridin-4-yl)-2-(trifluoromethyl)pyrimidine Chemical compound C1=NC(OC)=CC(C=2C=NC(=NC=2)C(F)(F)F)=C1 JZRIWCZIKIAFIJ-UHFFFAOYSA-N 0.000 description 1
- FTYPQSBSRANZPG-UHFFFAOYSA-N 5-chloro-2-[(1-oxidopyridin-1-ium-4-yl)oxymethyl]pyridine Chemical compound C1=C[N+]([O-])=CC=C1OCC1=CC=C(Cl)C=N1 FTYPQSBSRANZPG-UHFFFAOYSA-N 0.000 description 1
- ZLNXVAQEESDOGO-UHFFFAOYSA-N 5-methyl-3,4-dihydro-1H-pyrido[4,3-b]indole-2-carboxylic acid Chemical compound C12=CC=CC=C2N(C)C2=C1CN(C(O)=O)CC2 ZLNXVAQEESDOGO-UHFFFAOYSA-N 0.000 description 1
- RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical compound C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 description 1
- DSVVMMJBEFRDBT-UHFFFAOYSA-N 5H-imidazo[1,2-a]pyridin-6-one Chemical compound O=C1C=CC=2N(C=CN2)C1 DSVVMMJBEFRDBT-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- NJBMMMJOXRZENQ-UHFFFAOYSA-N 6H-pyrrolo[2,3-f]quinoline Chemical class c1cc2ccc3[nH]cccc3c2n1 NJBMMMJOXRZENQ-UHFFFAOYSA-N 0.000 description 1
- XAHAQVIJZAMMLO-UHFFFAOYSA-N 7-bromo-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole Chemical compound C1CNCC2=C1C1=CC=C(Br)C=C1N2 XAHAQVIJZAMMLO-UHFFFAOYSA-N 0.000 description 1
- TUSYOQIFTDTTON-UHFFFAOYSA-N 7-bromo-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-1-carboxylic acid Chemical compound N1C2=CC(Br)=CC=C2C2=C1C(C(=O)O)NCC2 TUSYOQIFTDTTON-UHFFFAOYSA-N 0.000 description 1
- QNONYJLPBQDBLC-UHFFFAOYSA-N 7-bromo-2,9-dimethyl-3,4-dihydro-1h-pyrido[3,4-b]indole Chemical compound CN1C2=CC(Br)=CC=C2C2=C1CN(C)CC2 QNONYJLPBQDBLC-UHFFFAOYSA-N 0.000 description 1
- PAIZAFYFNXIFSL-UHFFFAOYSA-N 7-bromo-8-fluoro-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carboxylic acid Chemical compound N1C2=CC(Br)=C(F)C=C2C2=C1CCN(C(=O)O)C2 PAIZAFYFNXIFSL-UHFFFAOYSA-N 0.000 description 1
- PFCCDEZMRKQBRZ-UHFFFAOYSA-N 7-bromo-9-methyl-1,2,3,4-tetrahydropyrido[3,4-b]indole Chemical compound C12=CC=C(Br)C=C2N(C)C2=C1CCNC2 PFCCDEZMRKQBRZ-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- UHBIKXOBLZWFKM-UHFFFAOYSA-N 8-hydroxy-2-quinolinecarboxylic acid Chemical compound C1=CC=C(O)C2=NC(C(=O)O)=CC=C21 UHBIKXOBLZWFKM-UHFFFAOYSA-N 0.000 description 1
- QKXURUVMUXPYQU-UHFFFAOYSA-N 9-methyl-1,2,3,4,5,6-hexahydropyrido[3,4-b]indole Chemical compound C1CC=CC2=C1C(CCNC1)=C1N2C QKXURUVMUXPYQU-UHFFFAOYSA-N 0.000 description 1
- STMNLEHELVDDKF-UHFFFAOYSA-N 9-methyl-1,2,3,4-tetrahydropyrido[3,4-b]indole Chemical compound C12=CC=CC=C2N(C)C2=C1CCNC2 STMNLEHELVDDKF-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- XPZJZMUSPBFGIW-UHFFFAOYSA-N C(CCC)OC(=O)N1CC=2N(C3=CC=C(C=C3C2CC1)Br)C Chemical compound C(CCC)OC(=O)N1CC=2N(C3=CC=C(C=C3C2CC1)Br)C XPZJZMUSPBFGIW-UHFFFAOYSA-N 0.000 description 1
- NKSYMWRZONILGK-UHFFFAOYSA-N CN1CC2=C(N(C=3C=C(C=CC23)N2CC=C(C=C2)C2=CC=C(C=C2)F)C)CC1 Chemical compound CN1CC2=C(N(C=3C=C(C=CC23)N2CC=C(C=C2)C2=CC=C(C=C2)F)C)CC1 NKSYMWRZONILGK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 101500028288 Homo sapiens Melanin-concentrating hormone Proteins 0.000 description 1
- 229940123502 Hormone receptor antagonist Drugs 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YCKCUKOLPXQNHF-UHFFFAOYSA-N [1-(oxan-2-yl)-6-oxopyridazin-4-yl] trifluoromethanesulfonate Chemical compound O=C1C=C(OS(=O)(=O)C(F)(F)F)C=NN1C1OCCCC1 YCKCUKOLPXQNHF-UHFFFAOYSA-N 0.000 description 1
- USEHFBIGOATLIA-UHFFFAOYSA-N [2-methyl-4-(trifluoromethyl)phenyl]boronic acid Chemical compound CC1=CC(C(F)(F)F)=CC=C1B(O)O USEHFBIGOATLIA-UHFFFAOYSA-N 0.000 description 1
- CBSXUFWMVOAHTK-UHFFFAOYSA-N [6-(trifluoromethyl)pyridin-3-yl]methanol Chemical compound OCC1=CC=C(C(F)(F)F)N=C1 CBSXUFWMVOAHTK-UHFFFAOYSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- VSSAZBXXNIABDN-UHFFFAOYSA-N cyclohexylmethanol Chemical compound OCC1CCCCC1 VSSAZBXXNIABDN-UHFFFAOYSA-N 0.000 description 1
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- YSLFMGDEEXOKHF-UHFFFAOYSA-N difluoro(iodo)methane Chemical compound FC(F)I YSLFMGDEEXOKHF-UHFFFAOYSA-N 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- HFYVCFSDZYRPRW-UHFFFAOYSA-N hydron;3-pyrrolidin-1-ylpropanoic acid;chloride Chemical compound Cl.OC(=O)CCN1CCCC1 HFYVCFSDZYRPRW-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- GPVFAGDOLJPMTQ-UHFFFAOYSA-N methyl 1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound N1C2=CC=CC=C2C2=C1CN(C(=O)OC)CC2 GPVFAGDOLJPMTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- KNPNGMXRGITFLE-UHFFFAOYSA-N methylperoxy(phenyl)borinic acid Chemical compound COOB(O)C1=CC=CC=C1 KNPNGMXRGITFLE-UHFFFAOYSA-N 0.000 description 1
- 125000004373 methylthiopropyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000001956 orexigenic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- UYESUYBXKHPUDU-UHFFFAOYSA-N phenyl(pyridin-2-yl)methanol Chemical compound C=1C=CC=NC=1C(O)C1=CC=CC=C1 UYESUYBXKHPUDU-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- HZGCZRCZOMANHK-UHFFFAOYSA-N pyrimidin-2-ylmethanol Chemical group OCC1=NC=CC=N1 HZGCZRCZOMANHK-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- QQPPIGFJBBKRHW-NDEPHWFRSA-N tert-butyl (2s)-2-[9-methyl-7-(2-oxo-4-phenylmethoxypyridin-1-yl)-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carbonyl]pyrrolidine-1-carboxylate Chemical compound C1=C2N(C)C=3CN(C(=O)[C@H]4N(CCC4)C(=O)OC(C)(C)C)CCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=CC=C1 QQPPIGFJBBKRHW-NDEPHWFRSA-N 0.000 description 1
- MBTZSOSZYIGVQZ-UHFFFAOYSA-N tert-butyl 5-(4-methylphenyl)sulfonyl-7-[2-oxo-4-[5-(trifluoromethyl)pyridin-2-yl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=CC(N3C(C=C(C=C3)C=3N=CC(=CC=3)C(F)(F)F)=O)=CC=C2C2=C1CCN(C(=O)OC(C)(C)C)C2 MBTZSOSZYIGVQZ-UHFFFAOYSA-N 0.000 description 1
- AGFVUHZREJWCIP-UHFFFAOYSA-N tert-butyl 5-methyl-7-(6-oxo-4-phenylmethoxypyridazin-1-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)N=CC=1OCC1=CC=CC=C1 AGFVUHZREJWCIP-UHFFFAOYSA-N 0.000 description 1
- DGQPVGSDFKJJNM-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-(pyridin-2-ylmethoxy)pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=CC=N1 DGQPVGSDFKJJNM-UHFFFAOYSA-N 0.000 description 1
- YLDDQVRZFLIGCN-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-(pyrimidin-2-ylmethoxy)pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=NC=CC=N1 YLDDQVRZFLIGCN-UHFFFAOYSA-N 0.000 description 1
- GSCRELYXKDNQTK-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-[[4-(trifluoromethyl)phenyl]methoxy]pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=C(C(F)(F)F)C=C1 GSCRELYXKDNQTK-UHFFFAOYSA-N 0.000 description 1
- CMSYABUHQSCIBD-UHFFFAOYSA-N tert-butyl 5-methyl-7-[2-oxo-4-[[5-(trifluoromethyl)pyridin-2-yl]methoxy]pyridin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=C(C(F)(F)F)C=N1 CMSYABUHQSCIBD-UHFFFAOYSA-N 0.000 description 1
- MRYWWNWCNMDZQC-UHFFFAOYSA-N tert-butyl 5-methyl-7-[6-oxo-4-[4-(trifluoromethyl)phenyl]pyridazin-1-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)N=CC=1C1=CC=C(C(F)(F)F)C=C1 MRYWWNWCNMDZQC-UHFFFAOYSA-N 0.000 description 1
- XDXNFIYZPAECMG-UHFFFAOYSA-N tert-butyl 6-bromo-9-methyl-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C12=CC(Br)=CC=C2N(C)C2=C1CCN(C(=O)OC(C)(C)C)C2 XDXNFIYZPAECMG-UHFFFAOYSA-N 0.000 description 1
- ULTZTTSBDMDNDO-UHFFFAOYSA-N tert-butyl 7-[4-(5-chloropyridin-2-yl)-2-oxopyridin-1-yl]-5-methyl-1,3,4,5-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=C2N=C3CN(C(=O)OC(C)(C)C)CCC3=C2C(C)C=C1N(C(C=1)=O)C=CC=1C1=CC=C(Cl)C=N1 ULTZTTSBDMDNDO-UHFFFAOYSA-N 0.000 description 1
- PCVURUQYDVIUFC-UHFFFAOYSA-N tert-butyl 7-[4-(5-chloropyridin-2-yl)-2-oxopyridin-1-yl]-5-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CCN(C(=O)OC(C)(C)C)CC=3C2=CC=C1N(C(C=1)=O)C=CC=1C1=CC=C(Cl)C=N1 PCVURUQYDVIUFC-UHFFFAOYSA-N 0.000 description 1
- BAUBWKAURYDLCD-UHFFFAOYSA-N tert-butyl 7-[4-(imidazo[1,2-a]pyridin-2-ylmethoxy)-2-oxopyridin-1-yl]-9-methyl-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC=CC2=NC(COC=3C=CN(C(C=3)=O)C3=CC=C4C=5CCN(CC=5N(C4=C3)C)C(=O)OC(C)(C)C)=CN21 BAUBWKAURYDLCD-UHFFFAOYSA-N 0.000 description 1
- XUZDVKOMNKEQPU-UHFFFAOYSA-N tert-butyl 7-[4-(imidazo[1,2-a]pyridin-6-ylmethoxy)-2-oxopyridin-1-yl]-9-methyl-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC2=NC=CN2C=C1COC(C=C1)=CC(=O)N1C1=CC=C2C(CCN(C3)C(=O)OC(C)(C)C)=C3N(C)C2=C1 XUZDVKOMNKEQPU-UHFFFAOYSA-N 0.000 description 1
- ZDGPECMTJLAZPA-UHFFFAOYSA-N tert-butyl 7-bromo-1,1,9-trimethyl-3,4-dihydropyrido[3,4-b]indole-2-carboxylate Chemical compound C12=CC=C(Br)C=C2N(C)C2=C1CCN(C(=O)OC(C)(C)C)C2(C)C ZDGPECMTJLAZPA-UHFFFAOYSA-N 0.000 description 1
- LBIVJCYSRHMGFV-UHFFFAOYSA-N tert-butyl 7-bromo-1-[[tert-butyl(dimethyl)silyl]oxymethyl]-9-methyl-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C12=CC=C(Br)C=C2N(C)C2=C1CCN(C(=O)OC(C)(C)C)C2CO[Si](C)(C)C(C)(C)C LBIVJCYSRHMGFV-UHFFFAOYSA-N 0.000 description 1
- DYMZKJGGHPAXCC-UHFFFAOYSA-N tert-butyl 7-bromo-9-methyl-1,3,4,9-tetrahydropyrido[4,3-b]indole-2-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CC2=C3C(C)C=C(Br)C=C3N=C21 DYMZKJGGHPAXCC-UHFFFAOYSA-N 0.000 description 1
- MRQKNQKVVBOWKU-UHFFFAOYSA-N tert-butyl 8-bromo-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carboxylate Chemical compound N1C2=CC=C(Br)C=C2C2=C1CCN(C(=O)OC(C)(C)C)C2 MRQKNQKVVBOWKU-UHFFFAOYSA-N 0.000 description 1
- BJVIPFASUFRPPV-UHFFFAOYSA-N tert-butyl 8-bromo-5-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole-2-carboxylate Chemical compound C12=CC(Br)=CC=C2N(C)C2=C1CN(C(=O)OC(C)(C)C)CC2 BJVIPFASUFRPPV-UHFFFAOYSA-N 0.000 description 1
- XLXJTPNHRMLRKJ-UHFFFAOYSA-N tert-butyl 9-(4-methylphenyl)sulfonyl-7-[2-oxo-4-[5-(trifluoromethyl)pyridin-2-yl]pyridin-1-yl]-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=CC(N3C(C=C(C=C3)C=3N=CC(=CC=3)C(F)(F)F)=O)=CC=C2C2=C1CN(C(=O)OC(C)(C)C)CC2 XLXJTPNHRMLRKJ-UHFFFAOYSA-N 0.000 description 1
- IGTVLEBBZGHQKZ-UHFFFAOYSA-N tert-butyl 9-methyl-7-[2-oxo-4-(pyridin-2-ylmethoxy)pyridin-1-yl]-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CN(C(=O)OC(C)(C)C)CCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=CC=N1 IGTVLEBBZGHQKZ-UHFFFAOYSA-N 0.000 description 1
- SQWBGVMNDWHMPM-UHFFFAOYSA-N tert-butyl 9-methyl-7-[2-oxo-4-[[6-(trifluoromethyl)pyridin-3-yl]methoxy]pyridin-1-yl]-3,4-dihydro-1h-pyrido[3,4-b]indole-2-carboxylate Chemical compound C1=C2N(C)C=3CN(C(=O)OC(C)(C)C)CCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=C(C(F)(F)F)N=C1 SQWBGVMNDWHMPM-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- WTVXIBRMWGUIMI-UHFFFAOYSA-N trifluoro($l^{1}-oxidanylsulfonyl)methane Chemical group [O]S(=O)(=O)C(F)(F)F WTVXIBRMWGUIMI-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D521/00—Heterocyclic compounds containing unspecified hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2053008P | 2008-01-11 | 2008-01-11 | |
| US61/020,530 | 2008-01-11 | ||
| US4867708P | 2008-04-29 | 2008-04-29 | |
| US61/048,677 | 2008-04-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100124251A KR20100124251A (ko) | 2010-11-26 |
| KR101614723B1 true KR101614723B1 (ko) | 2016-04-22 |
Family
ID=40429805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107017685A Active KR101614723B1 (ko) | 2008-01-11 | 2009-01-09 | Mch 길항물질로서 (1-아지논)-치환된 피리도인돌 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US8716308B2 (enExample) |
| EP (2) | EP2476680B1 (enExample) |
| JP (2) | JP5501251B2 (enExample) |
| KR (1) | KR101614723B1 (enExample) |
| CN (1) | CN101945872B (enExample) |
| AU (1) | AU2009204048B2 (enExample) |
| BR (1) | BRPI0907122B8 (enExample) |
| CA (1) | CA2727055C (enExample) |
| ES (1) | ES2523580T3 (enExample) |
| IL (1) | IL206594A (enExample) |
| MX (1) | MX2010007430A (enExample) |
| NZ (1) | NZ586120A (enExample) |
| WO (1) | WO2009089482A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2523580T3 (es) * | 2008-01-11 | 2014-11-27 | Albany Molecular Research, Inc. | Piridoindoles substituidos con (1-Azinona) |
| US9187455B2 (en) * | 2009-02-23 | 2015-11-17 | Hoffmann-La Roche Inc. | Substituted pyridazines as PDE10A inhibitors |
| US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
| US8637501B2 (en) | 2009-07-01 | 2014-01-28 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof |
| US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
| WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
| JP6129850B2 (ja) * | 2012-01-12 | 2017-05-17 | 武田薬品工業株式会社 | Mch受容体拮抗剤としてのベンゾイミダゾール誘導体 |
| HU230880B1 (hu) | 2015-04-15 | 2018-11-29 | Richter Gedeon Nyrt | Indol származékok |
| CN112739689B (zh) | 2018-12-07 | 2022-06-03 | 优迈特株式会社 | 含氟嘧啶化合物及其制造方法 |
| CN114901279A (zh) * | 2019-03-13 | 2022-08-12 | 洛克菲勒大学 | 用于治疗自身炎性疾病和癌症转移的cGAS的抑制剂 |
| US20230084144A1 (en) * | 2020-01-10 | 2023-03-16 | Consynance Therapeutics, Inc. | Therapeutic combinations of drugs and methods of using them |
| CN119504704A (zh) | 2020-05-19 | 2025-02-25 | 优迈特株式会社 | 含氟嘧啶化合物和含氟嘧啶酮化合物 |
| CA3206499A1 (en) * | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| JP7659651B2 (ja) | 2021-11-12 | 2025-04-09 | ユニマテック株式会社 | 含フッ素ピリミジン化合物、有害菌類防除剤および含フッ素ピリミジン化合物の製造方法 |
| HUP2200222A1 (hu) | 2022-06-17 | 2023-12-28 | Richter Gedeon Nyrt | MCHR1 antagonisták a Prader-Willi szindróma kezelésére |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007141200A1 (en) | 2006-06-02 | 2007-12-13 | Janssen Pharmaceutica N.V. | Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases |
Family Cites Families (205)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3514462A (en) * | 1966-10-21 | 1970-05-26 | Upjohn Co | 1 and 2 ethoxy 3,4,5,10 - tetrahydroazepino(3,4-b) and (2,3-b)indoles and corresponding amino derivatives thereof |
| CH649553A5 (de) | 1982-05-06 | 1985-05-31 | Sandoz Ag | Azepinoindole und verfahren zu deren herstellung. |
| EP0257915B1 (en) | 1986-08-11 | 1993-03-10 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
| US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
| IT1223343B (it) | 1987-11-03 | 1990-09-19 | Also Lab Sas | Formulazioni farmaceutiche per somministrazione transdermica |
| US4985422A (en) * | 1988-04-27 | 1991-01-15 | Glaxo Group Limited | Lactam derivatives |
| HU207078B (en) * | 1988-08-02 | 1993-03-01 | Glaxo Group Ltd | Process for producing lactam derivatives and pharmaceutical compositions comprising such compounds |
| US5223625A (en) * | 1988-12-22 | 1993-06-29 | Duphar International Research B.V. | Annelated indolo [3,2,-C]lactams |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| CA2050905A1 (en) | 1989-02-23 | 1990-08-24 | George R. Felt | Therapeutic aerosol formulations |
| GB8904551D0 (en) * | 1989-02-28 | 1989-04-12 | Glaxo Group Ltd | Chemical compounds |
| US4978669A (en) | 1989-06-08 | 1990-12-18 | Neurex Corporation | Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives |
| US5169852A (en) | 1989-06-08 | 1992-12-08 | Neurex Corporation | Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| CA2036337C (fr) * | 1990-02-15 | 2003-04-15 | Francois Clemence | Derives de la 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant |
| US5225407A (en) * | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| US5162336A (en) | 1990-06-21 | 1992-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists |
| US5187180A (en) * | 1990-07-26 | 1993-02-16 | Merck Frosst Canada, Inc. | (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes |
| US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
| US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| JP2951434B2 (ja) | 1991-04-18 | 1999-09-20 | 三菱製紙株式会社 | 電子写真感光体 |
| DE4130933A1 (de) * | 1991-09-13 | 1993-03-18 | Schering Ag | Neue (beta)-carbolinderivate, deren herstellung und verwendung in arzneimitteln |
| DE4240672A1 (de) * | 1992-11-24 | 1994-05-26 | Schering Ag | Neues Verfahren zur Herstellung von beta-Carbolinen |
| US5767131A (en) * | 1993-04-05 | 1998-06-16 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
| IL109220A0 (en) | 1993-04-05 | 1994-07-31 | Synaptic Pharma Corp | Dihydropyridines and new uses thereof |
| US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| GB9418326D0 (en) * | 1994-09-12 | 1994-11-02 | Lilly Industries Ltd | Pharmaceutical compounds |
| MX9700693A (es) * | 1994-07-26 | 1997-04-30 | Pfizer | Derivados del 4-indol. |
| DE4436190A1 (de) | 1994-10-10 | 1996-04-11 | Gerhard Prof Dr Bringmann | Halogenierte ß-Carbolin-Derivate, Verfahren zu ihrer Herstellung und Verwendung dieser Substanzen zur Hemmung der Atmungskette |
| US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| WO1996012721A1 (en) | 1994-10-20 | 1996-05-02 | American Home Products Corporation | Indole derivatives useful as serotonergic agents |
| US5466688A (en) * | 1994-10-20 | 1995-11-14 | American Home Products Corporation | Pyrido[3,4-B]indole derivatives as serotonergic agents |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| GB9508195D0 (en) | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
| US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| US6001866A (en) | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5972980A (en) * | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| HUP9801834A3 (en) | 1995-10-12 | 2000-06-28 | Supergen Inc Emeryville | Liposome formulations of 5beta steroids |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| WO1997031910A1 (en) | 1996-02-28 | 1997-09-04 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JP2000513375A (ja) | 1996-06-28 | 2000-10-10 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲンレセプター拮抗薬プロドラッグ |
| JP2000514061A (ja) | 1996-06-28 | 2000-10-24 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲン受容体拮抗物質 |
| US5932582A (en) * | 1996-06-28 | 1999-08-03 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| US5854245A (en) | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5811551A (en) * | 1996-08-13 | 1998-09-22 | Merck & Co., Inc. | Palladium catalyzed indolization |
| US6177440B1 (en) * | 1996-10-30 | 2001-01-23 | Eli Lilly And Company | Substituted tricyclics |
| US6713645B1 (en) * | 1996-10-30 | 2004-03-30 | Eli Lilly And Company | Substituted tricyclics |
| BR9908833A (pt) | 1998-03-17 | 2000-11-21 | Macef | Derivados, processo para a preparação dos mesmos, e, produto médico |
| IL129484A0 (en) | 1998-04-17 | 2000-02-29 | Lilly Co Eli | Substituted tricyclics |
| BR9911031A (pt) | 1998-05-20 | 2002-01-29 | Liposome Co Inc | Novas formulações em partìculas |
| EP1086105B1 (en) * | 1998-06-16 | 2006-03-01 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Fused azepinone cyclin dependent kinase inhibitors |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| US6451349B1 (en) | 1998-08-19 | 2002-09-17 | Quadrant Healthcare (Uk) Limited | Spray-drying process for the preparation of microparticles |
| AUPP494798A0 (en) | 1998-07-29 | 1998-08-20 | Pacific Biolink Pty Limited | Protective protein formulation |
| US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
| EP1142870A1 (en) * | 1998-12-14 | 2001-10-10 | Nuclear Receptor Research Limited | Novel ligands of nuclear receptor |
| EP1338272A1 (en) | 1998-12-21 | 2003-08-27 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate |
| US6294153B1 (en) | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| US6436367B1 (en) | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
| WO2000045792A1 (en) | 1999-02-03 | 2000-08-10 | Powderject Research Limited | Hydrogel particle formulations |
| AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
| JP2002538195A (ja) | 1999-03-08 | 2002-11-12 | パウダージェクト リサーチ リミテッド | 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達 |
| ATE244558T1 (de) | 1999-04-16 | 2003-07-15 | Novo Nordisk As | Trockene formbare arzneistoffformulierung |
| AR023574A1 (es) | 1999-04-23 | 2002-09-04 | Pharmacia & Upjohn Co Llc | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios |
| US6407092B1 (en) * | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| CA2375914A1 (en) | 1999-06-04 | 2000-12-14 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| US6713471B1 (en) * | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| BR0012084A (pt) | 1999-06-15 | 2002-04-02 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos |
| MY122278A (en) | 1999-07-19 | 2006-04-29 | Upjohn Co | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
| JP2003507410A (ja) | 1999-08-25 | 2003-02-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 乾燥粉末製剤からの放出調節 |
| US20010036481A1 (en) | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| MXPA02007052A (es) | 2000-01-20 | 2002-12-13 | Basilea Pharmaceutica Ag | Composiciones que se administran nasalmente y que contienen peptidos ciclicos. |
| US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| EP1129705A1 (en) | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
| US6890933B1 (en) * | 2000-02-24 | 2005-05-10 | President And Fellows Of Harvard College | Kinesin inhibitors |
| CO5300399A1 (es) * | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
| CO5261594A1 (es) | 2000-03-02 | 2003-03-31 | Smithkline Beecham Corp | Inhibidores de myt1 cinasa |
| WO2001068648A1 (en) | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| JP5000828B2 (ja) | 2000-03-15 | 2012-08-15 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | IkBキナーゼ阻害活性を有する置換ベーターカルボリン |
| ATE364381T1 (de) | 2000-04-17 | 2007-07-15 | Vectura Ltd | Formulierungen zur verwendung in inhalationsvorrichtungen |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| US6469020B2 (en) | 2000-05-15 | 2002-10-22 | Darwin Discovery, Ltd. | Hydroxamic and carboxylic acid derivatives |
| UA74826C2 (en) | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
| US6927223B1 (en) * | 2000-05-26 | 2005-08-09 | Washington State University Research Foundation | Use of serotonin agents for adjunct therapy in the treatment of cancer |
| US20020155084A1 (en) | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
| MXPA02012076A (es) * | 2000-06-07 | 2003-06-06 | Lilly Icos Llc | Compuestos quimicos. |
| WO2001098344A2 (en) | 2000-06-16 | 2001-12-27 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| WO2002004456A1 (en) | 2000-07-06 | 2002-01-17 | Pharmacia & Upjohn Company | SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES |
| JP2004509894A (ja) | 2000-09-20 | 2004-04-02 | ファルマシア・アンド・アップジョン・カンパニー | 置換アゼピノ[4,5−b]インドリン誘導体 |
| AU2002213419A1 (en) * | 2000-10-02 | 2002-04-15 | Lilly Icos Llc | Condensed pyridoindole derivatives |
| JP4246488B2 (ja) | 2000-10-03 | 2009-04-02 | リリー アイコス リミテッド ライアビリティ カンパニー | 化学化合物 |
| FI20002768A7 (fi) | 2000-12-18 | 2002-06-19 | Licentia Oy | Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus |
| CA2431028A1 (en) | 2000-12-18 | 2002-06-27 | Ho-Shen Lin | Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| US6849619B2 (en) * | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| CA2432122A1 (en) | 2000-12-20 | 2002-08-01 | Bristol-Myers Squibb Pharma Company | Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| CA2432185C (en) | 2000-12-20 | 2011-11-08 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| US7022856B2 (en) * | 2001-02-12 | 2006-04-04 | Lilly Icos Llc. | Carboline derivatives |
| CA2437718C (en) | 2001-02-12 | 2010-03-16 | Lilly Icos Llc | Carboline derivatives |
| GB0107106D0 (en) | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
| EP1383765B1 (en) | 2001-04-25 | 2006-12-13 | Lilly Icos LLC | Carboline derivatives as inhibitors of phosphodiesterase 5 (PDE5) for the treatment of cardiovascular diseases and erectile dysfunction |
| JP2004534017A (ja) | 2001-04-27 | 2004-11-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | Baceのインヒビター |
| EP1401835A1 (en) | 2001-06-05 | 2004-03-31 | Lilly Icos LLC | Carboline derivatives as pde-5 inhibitors |
| US6727264B1 (en) | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
| US20030019437A1 (en) | 2001-07-26 | 2003-01-30 | John Fore | Ungulate game animal feed system and method |
| GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| JP2005526691A (ja) * | 2001-08-08 | 2005-09-08 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 治療剤1H−ピリド[4,3−b]インドール |
| PT1418890E (pt) | 2001-08-16 | 2008-06-09 | Baxter Int | Formulações de micropartículas à base de propulsor |
| EP2116248A1 (en) * | 2001-09-05 | 2009-11-11 | Minerva Biotechnologies Corporation | Compositions and Methods of Treatment of Cancer |
| US20030232019A1 (en) | 2002-02-22 | 2003-12-18 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
| ES2718455T3 (es) | 2002-03-20 | 2019-07-02 | Civitas Therapeutics Inc | Formulaciones terapéuticas sostenidas inhalables |
| CA2484724C (en) | 2002-05-07 | 2007-01-16 | Ferring B.V. | Pharmaceutical formulations |
| US6951881B2 (en) * | 2002-05-10 | 2005-10-04 | Wyeth | (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands |
| US6906095B2 (en) * | 2002-05-10 | 2005-06-14 | Wyeth | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands |
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| AU2003277215A1 (en) | 2002-10-01 | 2004-04-23 | Predix Pharmaceuticals Holdings, Inc. | Novel neurokinin antagonists and methods of use thereof |
| US7250514B1 (en) * | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| GB0305553D0 (en) | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Compounds |
| EP1462103A1 (en) | 2003-03-25 | 2004-09-29 | Faust Pharmaceuticals | NO donors, combination products and uses as modulators of neurotransmitter release |
| EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| US7385055B2 (en) * | 2003-05-19 | 2008-06-10 | Board Of Trustees Of Michigan State University | Preparation of hymenialdisine derivatives and use thereof |
| EP1635818B1 (en) | 2003-06-06 | 2010-04-07 | Merck Sharp & Dohme Corp. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2004113336A1 (en) | 2003-06-16 | 2004-12-29 | Chroma Therapeutics Limited | Carboline and betacarboline derivatives for use as hdac enzyme inhibitors |
| EP1650206A4 (en) | 2003-08-01 | 2006-12-20 | Nippon Soda Co | PHENYLAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND ANTIOXIDANTS |
| NL1026826C2 (nl) * | 2003-08-13 | 2007-01-04 | Pharmacia Corp | Gesubstitueerde pyridinonen. |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| US7855295B2 (en) * | 2004-01-23 | 2010-12-21 | Novartis Vaccines And Diagnostics, Inc. | Tetrahydrocarboline compounds as anticancer agents |
| AU2005208938A1 (en) * | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc | Anti-viral therapeutics |
| US7994196B2 (en) * | 2004-02-12 | 2011-08-09 | Mitsubishi Tanabe Pharma Corporation | Indazole compound and pharmaceutical use thereof |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US20050187387A1 (en) * | 2004-02-25 | 2005-08-25 | Lynch John K. | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| WO2005108367A1 (en) | 2004-05-03 | 2005-11-17 | Envivo Pharmaceuticals, Inc. | Compounds for treatment of neurodegenerative diseases |
| UA87313C2 (ru) | 2004-05-12 | 2009-07-10 | Байер Кропсайенс Аг | Применение производного конденсированного азепинона для регулирования роста растений, композиция на его основе и способ регулирования роста растений |
| US20070254877A1 (en) | 2004-06-02 | 2007-11-01 | Takada Pharmaceutical Company Limited | Indole Derivative and Use for Treatment of Cancer |
| JP2008508356A (ja) | 2004-08-02 | 2008-03-21 | スミスクライン ビーチャム コーポレーション | Hpv感染に有用な化合物 |
| DE102004039382A1 (de) * | 2004-08-13 | 2006-02-23 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| AU2005314938B2 (en) | 2004-12-13 | 2011-06-09 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
| AU2005315319B2 (en) | 2004-12-17 | 2011-07-07 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
| US20060167259A1 (en) * | 2005-01-21 | 2006-07-27 | Cephalon, Inc. | Direct racemization of indole derivatives |
| WO2006081072A1 (en) * | 2005-01-24 | 2006-08-03 | Abbott Laboratories | Antagonists of the mglu receptor and uses thereof |
| WO2006089874A1 (en) | 2005-02-22 | 2006-08-31 | Gpc Biotech Ag | Benzo[2,3]azepino[4,5-b]indol-6-ones |
| DE102005016460A1 (de) * | 2005-04-11 | 2006-10-19 | Grünenthal GmbH | Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit |
| WO2006117212A2 (en) * | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| WO2006117221A1 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of azapaullones for preventing and treating pancreatic autoimmune disorders |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| WO2006122931A1 (en) * | 2005-05-20 | 2006-11-23 | Biovitrum Ab (Publ) | Beta-carboline derivatives and theri use as ghsr modulators |
| CA2606499C (en) * | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
| US8153671B2 (en) * | 2005-07-14 | 2012-04-10 | Irm Llc | Heterotetracyclic compounds as TPO mimetics |
| EA200800430A1 (ru) * | 2005-07-28 | 2008-06-30 | Бристол-Маерс Сквибб Компани | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов |
| US7749994B2 (en) * | 2005-08-12 | 2010-07-06 | Genentech, Inc. | Pentacyclic kinase inhibitors |
| WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
| EP1757607A1 (en) | 2005-08-24 | 2007-02-28 | Molisa GmbH | N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases |
| AU2006288153A1 (en) * | 2005-09-07 | 2007-03-15 | Msd K.K. | Bicyclic aromatic substituted pyridone derivative |
| US20070185184A1 (en) * | 2005-09-16 | 2007-08-09 | Serenex, Inc. | Carbazole derivatives |
| CA2623026A1 (en) * | 2005-09-23 | 2007-04-05 | Schering Corporation | Fused tetracyclic mglur1 antagonists as therapeutic agents |
| WO2007062175A2 (en) | 2005-11-21 | 2007-05-31 | Amgen Inc. | Spiro-substituted tricyclic heterocycles cxcr3 antagonists |
| CA2633243C (en) | 2005-12-15 | 2014-05-27 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| JP2009519974A (ja) | 2005-12-16 | 2009-05-21 | ジェネンテック・インコーポレーテッド | 四環系キナーゼ阻害剤 |
| CN101341135B (zh) * | 2005-12-21 | 2013-08-14 | 詹森药业有限公司 | 治疗mch-1介导的疾病的取代的吡嗪酮衍生物 |
| KR20080110912A (ko) | 2006-04-19 | 2008-12-19 | 노파르티스 아게 | 인다졸 화합물 및 cdc7의 억제 방법 |
| DE102006019597A1 (de) | 2006-04-27 | 2007-10-31 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| US20080124319A1 (en) * | 2006-05-16 | 2008-05-29 | Charalabos Pothoulakis | Methods for treating inflammation by disrupting MCH-mediated signaling |
| MX2008014672A (es) * | 2006-05-19 | 2009-03-09 | Abbott Lab | Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central. |
| WO2007142217A1 (ja) * | 2006-06-07 | 2007-12-13 | Banyu Pharmaceutical Co., Ltd. | 1-フェニルピリドン誘導体 |
| CN101074207B (zh) | 2006-06-08 | 2014-03-26 | 中国科学院成都有机化学有限公司 | 一类水溶性的手性二胺衍生物及其应用和制备 |
| CN101108859A (zh) | 2006-07-17 | 2008-01-23 | 上海恒瑞医药有限公司 | 长春碱类化合物、其制备方法及其在医药上的用途 |
| RU2317989C1 (ru) | 2006-08-24 | 2008-02-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ АЗЕПИНО[4,3-b]ИНДОЛЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| BRPI0716579A2 (pt) * | 2006-08-25 | 2013-10-08 | Boehringer Ingelheim Int | Derivados de piridona com atividade antagonista ao mch e medicamentos que compreendem estes compostos |
| DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| WO2008046155A1 (en) | 2006-10-20 | 2008-04-24 | Dia-B Tech Limited | Methods for regulating glucose homeostasis and agents therefor |
| RU2329044C1 (ru) | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
| ES2483866T3 (es) * | 2006-12-05 | 2014-08-08 | Janssen Pharmaceutica Nv | Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1 |
| WO2008081282A2 (en) | 2006-12-20 | 2008-07-10 | Glenmark Pharmaceuticals S.A. | Process for the synthesis of n9-(3,5-dichloro-4-pyridyl)-6- difluoromethoxybenzo(4,5)furo(3,2-c)pyridine-9-carboxamide and salts thereof |
| CA2673654A1 (en) * | 2007-01-10 | 2008-07-17 | Albany Molecular Research, Inc. | 5-pyridinone substituted indazoles |
| AU2008204915B2 (en) | 2007-01-10 | 2013-02-07 | Albany Molecular Research, Inc. | 5-furopyridinone substituted indazoles |
| WO2008103470A2 (en) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
| DE102007009319A1 (de) | 2007-02-22 | 2008-08-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE102007009235A1 (de) | 2007-02-22 | 2008-09-18 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| US8063089B2 (en) | 2007-02-28 | 2011-11-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibitors of nucleophosmin (NPM) and methods for inducing apoptosis |
| KR102238390B1 (ko) | 2007-03-12 | 2021-04-08 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| TW200902016A (en) | 2007-05-22 | 2009-01-16 | Taigen Biotechnology Co Ltd | Kinesin inhibitors |
| EP2003129B1 (en) | 2007-06-11 | 2017-08-09 | Nerviano Medical Sciences S.r.l. | 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives |
| KR20100040872A (ko) | 2007-06-25 | 2010-04-21 | 뉴로젠 코포레이션 | 피페라지닐 옥소알킬 테트라하이드로-베타-카르볼린 및 이의 관련 유사체 |
| CA2689945A1 (en) * | 2007-06-26 | 2008-12-31 | Astrazeneca Ab | 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors |
| BRPI0814772A2 (pt) | 2007-07-21 | 2015-03-03 | Albany Molecular Res Inc | Indazóis substituídos por 5-piridinona |
| WO2009022104A1 (en) | 2007-08-13 | 2009-02-19 | De Montfort University | Fascaplysin derivatives and their use in the treatment of cancer |
| CA2597193A1 (en) | 2007-08-13 | 2009-02-13 | De Montfort University | Compounds and uses |
| AU2008295483B2 (en) | 2007-08-29 | 2013-11-21 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
| US11202775B2 (en) * | 2007-09-25 | 2021-12-21 | Minerva Biotechnologies Corporation | Methods for treatment of cancer |
| ES2523580T3 (es) * | 2008-01-11 | 2014-11-27 | Albany Molecular Research, Inc. | Piridoindoles substituidos con (1-Azinona) |
| US9625475B2 (en) * | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
| US8637501B2 (en) * | 2009-07-01 | 2014-01-28 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof |
| US8618299B2 (en) * | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
| US9073925B2 (en) * | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| US8629158B2 (en) * | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
| WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
-
2009
- 2009-01-09 ES ES12163813.4T patent/ES2523580T3/es active Active
- 2009-01-09 US US12/351,561 patent/US8716308B2/en active Active
- 2009-01-09 KR KR1020107017685A patent/KR101614723B1/ko active Active
- 2009-01-09 JP JP2010542381A patent/JP5501251B2/ja active Active
- 2009-01-09 NZ NZ586120A patent/NZ586120A/en unknown
- 2009-01-09 MX MX2010007430A patent/MX2010007430A/es active IP Right Grant
- 2009-01-09 CA CA2727055A patent/CA2727055C/en active Active
- 2009-01-09 CN CN200980105529.7A patent/CN101945872B/zh active Active
- 2009-01-09 EP EP12163813.4A patent/EP2476680B1/en active Active
- 2009-01-09 EP EP09700411A patent/EP2240481A1/en not_active Withdrawn
- 2009-01-09 BR BRPI0907122A patent/BRPI0907122B8/pt active IP Right Grant
- 2009-01-09 WO PCT/US2009/030646 patent/WO2009089482A1/en not_active Ceased
- 2009-01-09 AU AU2009204048A patent/AU2009204048B2/en active Active
-
2010
- 2010-06-24 IL IL206594A patent/IL206594A/en active IP Right Grant
-
2014
- 2014-03-11 JP JP2014047896A patent/JP2014129417A/ja active Pending
- 2014-03-24 US US14/223,151 patent/US9296743B2/en active Active
-
2016
- 2016-02-17 US US15/045,652 patent/US9650378B2/en active Active
-
2017
- 2017-04-03 US US15/477,984 patent/US20170204095A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007141200A1 (en) | 2006-06-02 | 2007-12-13 | Janssen Pharmaceutica N.V. | Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2476680A1 (en) | 2012-07-18 |
| CA2727055C (en) | 2016-12-20 |
| AU2009204048B2 (en) | 2013-08-01 |
| NZ586120A (en) | 2012-07-27 |
| US20140206696A1 (en) | 2014-07-24 |
| BRPI0907122B8 (pt) | 2021-05-25 |
| KR20100124251A (ko) | 2010-11-26 |
| BRPI0907122B1 (pt) | 2019-04-16 |
| MX2010007430A (es) | 2010-12-21 |
| US8716308B2 (en) | 2014-05-06 |
| JP5501251B2 (ja) | 2014-05-21 |
| BRPI0907122A2 (pt) | 2015-07-14 |
| US20100331339A9 (en) | 2010-12-30 |
| JP2014129417A (ja) | 2014-07-10 |
| CN101945872A (zh) | 2011-01-12 |
| ES2523580T3 (es) | 2014-11-27 |
| US9650378B2 (en) | 2017-05-16 |
| AU2009204048A1 (en) | 2009-07-16 |
| US20170204095A1 (en) | 2017-07-20 |
| CN101945872B (zh) | 2014-07-23 |
| WO2009089482A1 (en) | 2009-07-16 |
| US20090275590A1 (en) | 2009-11-05 |
| CA2727055A1 (en) | 2009-07-16 |
| JP2011509937A (ja) | 2011-03-31 |
| IL206594A0 (en) | 2010-12-30 |
| US9296743B2 (en) | 2016-03-29 |
| EP2240481A1 (en) | 2010-10-20 |
| US20160159798A1 (en) | 2016-06-09 |
| EP2476680B1 (en) | 2014-08-27 |
| IL206594A (en) | 2015-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101614723B1 (ko) | Mch 길항물질로서 (1-아지논)-치환된 피리도인돌 | |
| US11390609B2 (en) | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof | |
| AU2008279321B2 (en) | 5-pyridinone substituted indazoles | |
| EP2448585B1 (en) | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof | |
| AU2008204915B2 (en) | 5-furopyridinone substituted indazoles | |
| WO2011003007A1 (en) | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof | |
| TW201410669A (zh) | 作為呼吸道融合病毒之抗病毒劑的新穎經雜環取代之1,3-二氫-2h-苯并咪唑-2-酮衍生物 | |
| HK1169111A (en) | (1-azinone)-substituted pyridoindoles | |
| HK1142608B (en) | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20100809 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| AMND | Amendment | ||
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20131220 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150422 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20151104 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20150422 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20151204 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20151104 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2015101007288 Request date: 20151204 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20151204 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20151204 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20150722 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20131220 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20100812 Patent event code: PB09011R02I |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20160201 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20160105 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20160418 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20160419 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20190416 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190416 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200407 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210408 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230327 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240320 Start annual number: 9 End annual number: 9 |